On November 4, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, reported the release of an abstract for the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition evaluating long-term safety and tolerability of Actimab-A (lintuzumab-Ac225) in combination with CLAG-M intensive salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract presents follow-up from a Phase 1 study of Actimab-A plus CLAG-M, with a focused analysis of blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. These safety findings complement efficacy data previously presented at ASH (Free ASH Whitepaper) 2022, which reported estimated one-year and two-year overall survival of 59% and 32%, respectively, in patients previously treated with venetoclax and 51% and 19%, respectively, in patients with TP53 mutated AML. Together, these observations support further evaluation of Actimab-A as a potential mutation agnostic therapeutic backbone for CD33-positive AML, including in difficult-to-treat populations, while addressing the importance of recovery and the ability to proceed to allogeneic hematopoietic cell transplantation.
"These long-term safety findings support our strategy to advance Actimab-A as a potential mutation-agnostic therapeutic backbone for AML," said Sandesh Seth, Actinium’s Chairman and CEO. "The previously reported clinical activity of Actimab-A plus CLAG-M, including in patients whose disease has failed venetoclax-based therapy and those with TP53 mutations, reinforces its potential to address difficult-to-treat disease. Together with the long-term safety follow-up, these observations support further clinical evaluation of Actimab-A in combination regimens, with the goal of improving outcomes and expanding treatment options for patients with resistant disease and limited therapeutic alternatives."
Actimab-A ASH (Free ASH Whitepaper) 2026 Presentation Details
Abstract Title: Long-Term Safety and Tolerability after Intensive Salvage therapy with CLAG-M for Relapsed/Refractory AML
Session Title: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Presenting Author: Sameem Abedin, MD, Medical College of Wisconsin
Location: Ernest N. Morial Convention Center, Hall F
Date: Sunday, December 13, 2026
Time: 6:00 PM – 8:00 PM
(Press release, Actinium Pharmaceuticals, NOV 4, 2026, View Source [SID1234674155])